Skip to main content

Table 1 Associations of CK19 expression and presence of MVI with clinicopathological characteristics in patients with HCC

From: Individual and joint influence of cytokeratin 19 and microvascular invasion on the prognosis of patients with hepatocellular carcinoma after hepatectomy

Characteristic

CK19(−)

CK19(+)

P

MVI(−)

MVI(+)

P

CK19(−)/MVI(−)

CK19(−)/MVI(+)

CK19(+)/MVI(−)

CK19(+)/MVI(+)

P

Age (years)

49.94 ± 10.51

46.76 ± 11.64

0.020

49.59 ± 10.80

48.75 ± 10.91

0.469

50.18 ± 10.48

49.62 ± 10.57

46.71 ± 12.04

46.78 ± 11.52

0.134

Sex

 Male

227 (84.1%)

67 (81.7%)

0.613

151 (81.6%)

143 (85.6%)

0.319

126 (81.8%)

101 (87.1%)

25 (80.6%)

42 (82.4%)

0.654

 Female

43 (15.9%)

15 (18.3%)

 

34 (18.4%)

24 (14.4%)

 

28 (18.2%)

15 (12.9%)

6 (19.4%)

9 (17.6%)

 

BCLC stage

 0

10 (3.7%)

5 (6.1%)

0.238

12 (6.5%)

3 (1.8%)

0.086

7 (4.5%)

3 (2.6%)

5 (16.1%)

0 (0%)

0.003

 A

181 (67.0%)

60 (73.2%)

 

122 (65.9%)

119 (71.3%)

 

105 (68.2%)

76 (65.5%)

17 (54.8%)

43 (84.3%)

 

 B

79 (29.3%)

17 (20.7%)

 

51 (27.6%)

45 (26.9%)

 

42 (27.3%)

37 (31.9%)

9 (29.0%)

8 (15.7%)

 

HBsAg

 Negative

35 (13.0%)

11 (13.4%)

1.000

20 (10.8%)

26 (15.6%)

0.207

16 (10.4%)

19 (16.4%)

4 (12.9%)

7 (13.7%)

0.549

 Positive

235 (87.0%)

71 (86.6%)

 

165 (89.2%)

141 (84.4%)

 

138 (89.6%)

97 (83.6%)

27 (87.1%)

44 (86.3%)

 

HBV-DNA (IU/ml)

  < 5 × 102

90 (33.3%)

32 (39.0%)

0.356

63 (34.1%)

59 (35.3%)

0.823

51 (33.1%)

39 (33.6%)

12 (38.7%)

20 (39.2%)

0.823

 ≧5 × 102

180 (66.7%)

50 (61.0%)

 

122 (65.9%)

108 (64.7)

 

103 (66.9%)

77 (66.4%)

19 (61.3%)

31 (60.8%)

 

Anti-HCV

 Negative

266 (98.5%)

80 (97.6%)

0.627

182 (98.4%)

164 (98.2%)

1.000

152 (98.7%)

114 (98.3%)

30 (96.8%)

50 (98.0%)

0.896

 Positive

4 (1.5%)

2 (2.4%)

 

3 (1.6%)

3 (1.8%)

 

2 (1.3%)

2 (1.7%)

1 (3.2%)

1 (2.0%)

 

Tumor diameter (cm)

5.00 (3.50, 7.50)

4.75 (3.5, 8.00)

0.383

4.50 (3.50, 7.00)

5.50 (3.50, 8.50)

0.008

4.75 (3.50, 7.00)

6.00 (3.50, 8.50)

4.00 (2.5, 6.00)

5.00 (3.50, 10.00)

0.017

Tumor number

 1

193 (71.5%)

65 (79.3%)

0.200

140 (75.7%)

118 (70.7%)

0.335

117 (76.0%)

76 (65.5%)

23 (74.2%)

42 (82.4%)

0.098

 ≧2

77 (28.5%)

17 (20.7%)

 

45 (24.3%)

49 (29.3%)

 

37 (24.0%)

40 (34.5%)

8 (25.8%)

9 (17.6%)

 

Tumor envelope

 Complete

230 (85.2%)

66 (80.5%)

0.305

164 (88.6%)

132 (79.0%)

0.019

134 (87.0%)

96 (82.8%)

30 (96.8%)

36 (70.6%)

0.008

 Incomplete

40 (14.8%)

16 (19.5%)

 

21 (11.4%)

35 (21.0%)

 

20 (13.0%)

20 (17.2%)

1 (3.2%)

15 (29.4%)

 

Ascites

           

 No

249 (92.2%)

73 (89.0%)

0.370

170 (91.9%)

152 (91.0%)

0.849

143 (92.9%)

106 (91.4%)

27 (87.1%)

46 (90.2%)

0.742

 Yes

21 (7.8%)

9 (11.0%)

 

15 (8.1%)

15 (9.0%)

 

11 (7.1%)

10 (8.6%)

4 (12.9%)

5 (9.8%)

 

AFP (ng/ml)

 <400

180 (66.7%)

31 (37.8%)

< 0.001

129 (69.7%)

82 (49.1%)

< 0.001

115 (74.7%)

65 (56.0%)

14 (45.2%)

17 (33.3%)

< 0.001

  ≥ 400

90 (33.3%)

51 (62.2%)

 

56 (30.3%)

85 (50.9%)

 

39 (25.3%)

51 (44.0%)

17 (554.8%)

34 (66.7%)

 

WBC (*109/L)

6.06 (4.88, 7.22)

5.40 (4.55, 6.80)

0.050

5.73 (4.66, 7.12)

6.06 (4.91, 7.16)

0.246

5.94 (4.74, 7.26)

6.17 (5.13, 7.16)

5.18 (4.55, 6.48)

5.73 (4.53, 7.31)

0.094

N% (%)

57.91 ± 9.96

57.17 ± 9.96

0.557

56.95 ± 9.87

58.61 ± 10.01

0.118

57.21 ± 9.96

58.83 ± 9.93

55.45 ± 9.42

58.09 ± 10.26

0.352

L% (%)

29.93 ± 8.47

30.05 ± 9.06

0.910

30.24 ± 8.72

29.64 ± 8.48

0.510

30.09 ± 8.49

29.72 ± 8.47

31.03 ± 9.87

29.45 ± 8.57

0.855

HB (g/L)

137.02 ± 17.20

140.01 ± 17.43

0.170

135.28 ± 17.43

140.43 ± 16.74

0.005

134.30 ± 17.08

140.64 ± 16.75

140.13 ± 18.63

139.94 ± 16.85

0.012

PLT (*109/L)

209.92 ± 77.74

198.43 ± 81.61

0.247

208.52 ± 83.84

205.82 ± 72.79

0.749

211.92 ± 85.27

207.25 ± 66.72

191.61 ± 75.35

202.57 ± 85.66

0.585

FPG (mmol/L)

4.71 (4.31, 5.22)

4.73 (4.28, 5.14)

0.792

4.76 (4.31, 5.22)

4.66 (4.30, 5.16)

0.326

4.74 (4.29, 5.22)

4.68 (4.33, 5.22)

4.84 (4.40, 5.24)

4.65 (4.23, 5.10)

0.605

PT (s)

13.09 ± 1.11

13.31 ± 1.25

0.131

13.19 ± 1.11

13.09 ± 1.19

0.435

13.17 ± 1.07

12.99 ± 1.15

13.29 ± 1.30

13.32 ± 1.24

0.280

INR

1.06 ± 0.12

1.07 ± 0.13

0.441

1.06 ± 0.12

1.06 ± 0.12

0.804

1.06 ± 0.12

1.06 ± 0.12

1.08 ± 0.14

1.07 ± 0.12

0.838

TBiL (μmol/L)

11.40 (8.38, 15.53)

11.30 (8.10, 14.83)

0.549

11.00 (8.10, 15.30)

11.60 (8.70, 15.30)

0.402

10.90 (8.10, 15.23)

11.75 (9.40, 16.58)

13.20 (8.10, 16.20)

11.20 (8.10, 13.80)

0.359

Alb (g/L)

41.08 ± 4.28

42.12 ± 4.45

0.056

41.16 ± 4.01

41.50 ± 4.48

0.453

40.91 ± 3.87

41.31 ± 4.78

42.40 ± 4.49

41.95 ± 4.47

0.220

PA (mg/L)

197.50 (156.75, 244.25)

192.00 (139.00, 247.00)

0.610

203.00 (157.00, 243.00)

191.00 (150.00, 249.00)

0.691

198.50 (157.50, 242.00)

195.50 (154.75, 255.25)

218.00 (139.00, 257.00)

180.00 (139.00, 233.00 )

0.555

ALT (U/L)

34.50 (24.00, 47.00)

30.50 (22.00, 39.00)

0.099

33.00 (22.00, 45.50)

33.00 (24.00, 44.00)

0.936

32.50 (22.00, 46.00)

36.50 (24.25, 47.75)

34.00 (22.00, 41.00)

30.00 (22.00, 39.00)

0.196

AST (U/L)

36.00 (27.00, 49.00)

33.00 (25.50, 45.25)

0.195

33.00 (25.50, 46.00)

36.00 (29.00, 52.00)

0.032

35.00 (26.00, 47.00)

37.00 (29.00, 53.75)

29.00 (23.00, 40.00)

35.00 (28.00, 48.00)

0.047

GGT (U/L)

53.00 (33.00, 104.00)

54.00 (31.75, 91.75)

0.692

50.00 (29.00, 92.00)

57.00 (36.00, 105.00)

0.026

51.00 (30.00, 96.50)

57.00 (36.00, 109.00)

43.00 (26.00, 74.00)

57.00 (36.00, 104.00)

0.125

ALP (U/L)

63.00 (50.00, 81.00)

61.00 (45.00, 84.25)

0.638

59.00 (45.00, 78.50)

66.00 (53.00, 88.00)

0.016

59.50 (47.00, 78.00)

67.00 (55.25, 92.75)

56.00 (42.00, 85.00)

64.00 (48.00, 84.00)

0.085

MVI

           

 Negative

154 (57.0%)

31 (37.8%)

0.002

        

 Positive

116 (43%)

51 (62.2%)

         
  1. Values are mean ± SD, n (%), or median (interquartile range), unless otherwise noted
  2. Abbreviations: AFP alpha-fetoprotein, Alb albumin, ALP alkaline phosphatase, ALT alanine aminotransferase, anti-HCV antibodies against hepatitis C virus, AST aspartate aminotransferase, BCLC Barcelona Clinic liver cancer, CK19 cytokeratin 19, FPG fasting plasma glucose, GGT γ-glutamyl transpeptidase, HB hemoglobin, HBsAg hepatitis B surface antigen, INR international normalized ratio, L% lymphocyte percentage; N% neutrophil percentage, MVI microvascular invasion, PA prealbumin, PLT blood platelets, PT prothrombin time, TBiL total bilirubin, WBC white blood cells